Pharsight

Naropin is owned by Fresenius Kabi Usa.

Naropin contains Ropivacaine Hydrochloride.

Naropin has a total of 4 drug patents out of which 1 drug patent has expired.

Expired drug patents of Naropin are:

Naropin was authorised for market use on 24 September, 1996.

Naropin is available in solution;injection dosage forms.

The generics of Naropin are possible to be released after 28 November, 2026.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8118802	FRESENIUS KABI USA	Connector for packaging containing medical fluids and packaging for medical fluids	May, 2023 (16 days ago)
US8162915	FRESENIUS KABI USA	Connector for packings containing medical liquids, and corresponding packing for medical liquids	May, 2024 (11 months from now)
US7828787	FRESENIUS KABI USA	Connector for packaging containing medical fluids and packaging for medical fluids	Oct, 2025 (2 years from now)
US7857802	FRESENIUS KABI USA	Connector for medical liquid-containing packages and medical liquid-containing packages	Nov, 2026 (3 years from now)

Do you want to check out NAROPIN patents from before 2022?

Market Authorisation Date: 24 September, 1996

Treatment: NA

Dosage: SOLUTION;INJECTION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2 mg/mL, 5 mg/mL and 10 mg/mL, 20 mL, 30 mL and 20 mL vials	13 Nov, 2006	1	17 Jul, 2014	23 Sep, 2014	Extinguished
2 mg/mL, 100 mL	30 Jan, 2015	1	13 Jul, 2016	28 Nov, 2026	Eligible
2 mg/mL, 200 mL	03 Sep, 2015	1	16 Mar, 2018	28 Nov, 2026	Extinguished